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Abstract 
Rapid prototyping of bone tissue engineering constructs often utilizes elevated temperatures, organic 
solvents and/or UV light for materials processing. These harsh conditions may prevent the incorporation of 
cells and therapeutic proteins in the fabrication processes. Here we developed a method for using 
bioprinting to produce constructs from a thermoresponsive microparticulate material based on poly(lactic-
co-glycolic acid) at ambient conditions. These constructs could be engineered with yield stresses of up to 
1.22 MPa and Young’s moduli of up to 57.3 MPa which are within the range of properties of human 
cancellous bone. Further study showed that protein-releasing microspheres could be incorporated into the 
bioprinted constructs. The release of the model protein lysozyme from bioprinted constructs was 
sustainted for a period of 15 days and a high degree of protein activity could be measured up to day 9. This 
work suggests that bioprinting is a viable route to the production of mechanically strong constructs for 
bone repair under mild conditions which allow the inclusion of viable cells and active proteins. 
1. Introduction 
Recent years have seen the development of a number of approaches utilising additive manufacturing 
techniques such as selective laser sintering [1, 2], stereolithography [3-5], fused filament fabrication [6-8] 
and 3D printing [9-12] for the production of custom, defect-matched constructs for bone repair. These 
approaches require the ceramic and polymeric materials which are used with them to be processed by the 
application of high temperatures [2, 6-8, 10, 11], ultraviolet light [3-5] or organic solvents [9, 12]. Whilst 
these harsh processing conditions cause little concern for the production of acellular scaffolds they have 
prevented the incorporation of cells and therapeutic biomolecules during the fabrication process. Post-
fabrication addition of proteins and cells is often associated with the inability to provide long-term delivery 
and uneven seeding respectively. More importantly, it prevents these elements from being patterned 
within constructs to create functional heterogeneity. It is therefore important to develop production 
processes which are compatible with the inclusion of cells and biomolecules. 
Bioprinting may provide a solution to this problem since it allows the fabrication of tissue engineered 
constructs at ambient conditions. To-date this approach has predominantly been used to produce hydrogel 
constructs since these are typically the only class of materials which can be processed under such mild 
conditions [13-20]. However there are issues with the use of hydrogel materials in orthopaedic applications 
including the very large disparity between their mechanical properties and those of bone [14, 15, 19, 20]. In 
addition to the inability of such weak materials to endure relevant in vivo loads, the low stiffness of 
hydrogels may inhibit the osteogenic differentiation of both endogenous and exogenous stem cells [21]. 
A thermoresponsive microparticulate material based on a blend of poly(L-lactic-co-glycolic acid) (PLGA) and 
polyethylene glycol (PEG) may overcome these issues. When mixed with aqueous carrier fluids at room 
temperature, these PLGA-based microparticles form extrudable pastes which can be formed to the desired 
scaffold shape. Incubation of these pastes at 37˚C and surrounded by aqueous fluid leads to 
thermoresponsive liquid sintering and the formation of porous solid constructs [22-27]. These constructs 
can be engineered with mechanical properties which are comparable to those of human cancellous bone 
[22-25, 28-31]. Previous studies utilising this material have shown that proteins [24, 26, 27] and cells [22, 
24] can tolerate the mixing and extrusion processes whilst maintaining activity and viability respectively. 
Encapsulated proteins can be delivered over several weeks [27] and the microporosity which is inherent to 
these constructs may also have beneficial effects on tissue ingrowth and angiogenesis in vivo. 
The primary purpose in developing this material was to formulate an injectable bone defect filler but we 
postulated that its ability to be delivered by injection would also make it highly suitable for use with 
extrusion based additive manufacturing techniques. Presented here is the first assessment of the feasibility 
of using the Fab@Home bioprinting platform [14, 17, 18, 32] in conjunction with PLGA-based microparticle 
pastes to fabricate bone tissue engineering constructs at ambient conditions. Particular emphasis is placed 
on achieving the incorporation of viable cells and active proteins into the bioprinting process to produce 
living constructs which have appropriate mechanical properties for implantation into bone defects. 
2. Materials & Methods 
2.1. Production and Sintering of PLGA/PEG Blend Microparticles 
Poly(lactic-co-glycolic acid) (PLGA) (85:15 lactide:glycolide, 53 kDa, Evonik Biomaterials, Birmingham, AL, 
USA) was melt blended at 90oC with poly(ethylene glycol) (PEG) (400 Da, Clariant, Leeds, UK) in a 93.5:6.5 
(w:w) ratio. This melt blend was then milled in a Krups F203 mill which had been pre-cooled with liquid 
nitrogen. The resulting powder was manually sieved using analytical test sieves (Retsch (UK), Castleford, 
UK) to select the 50 – 100 μm size fraction. 
To produce constructs these PLGA-PEG microparticles were suspended in aqueous carrier fluids to form 
dense pastes which were dispensed via bioprinting and then sintered by incubation in a humidified 
environment at 37oC for two hours, followed by submersion in 0.9% (w/v) sodium chloride in the same 
environment for a further 22 hours. 
2.2. PLGA-Based Microsphere Manufacture 
PLGA-PEG-PLGA triblock copolymer (‘Triblock’) was fabricated by a previously-published protocol [33]. Gel 
permeation chromatography measurements of the synthesized triblock copolymer using a PL-GPC 120 
(Polymer Labs) indicated a molecular weight of 4590 Da and a polydispersity index of 1.60.  
PLGA and Triblock were dissolved in dichloromethane at 14 and 6% (w/v) respectively to a total polymer 
mass of 1 g. A small amount of water (2% (v/v) relative to the organic phase) was added to the polymer 
solution and this combination was homogenized for two minutes to form a primary emulsion using a 
Silverson L5M homogenizer (Silverson Machines Ltd., Chesham, UK) at 4000 rpm. The primary emulsion 
was then added to an aqueous solution of 0.3% (w/v) poly(vinyl alcohol) (PVA, 87 – 89% hydrolysed, 13 – 23 
kDa, Sigma-Aldrich) and homogenized for two minutes at 2000 rpm to form a secondary emulsion. The 
secondary emulsion was stirred for 4 hours and the hardened microspheres collected under vacuum 
filtration (0.2 µm filter mesh), snap frozen in liquid nitrogen and lyophilized for 48 hours. Lysozyme was 
incorporated into microspheres by dissolution in the water used to form the primary emulsion (9 mg 
human serum albumin carrier protein (Sigma-Aldrich) and 1 mg lysozyme from chicken egg white (Sigma-
Aldrich)). Primary emulsion production was carried out in 30 mL PTFE beakers (VWR International, 
Lutterworth, UK) and secondary emulsion in a 250 mL borosilicate glass beaker (Fisher Scientific) using 200 
mL of PVA solution. 
2.3. Immortalized Human Mesenchymal Stem Cells 
Primary hMSCs (bone marrow-derived, TCS Cellworks, Buckingham, UK) were immortalized (ihMSCs) using 
a previously published protocol [34]. ihMSCs were cultured in Dulbecco’s modified Eagle medium (Life 
Technologies, Paisley, UK) supplemented with 10% (v/v) foetal bovine serum (Sigma-Aldrich, Poole, UK), 1% 
(v/v) L-glutamine (Sigma-Aldrich), 1% (v/v) penicillin /streptomycin (Life Technologies) and 1% (v/v) non-
essential amino acids (Sigma-Aldrich). Cultures were maintained at 37oC and 5% (v/v) CO2 as monolayers on 
tissue culture treated polystyrene. At 80% confluency cells were passaged by trypsinisation and reseeded 
between 1/5th and 1/8th of pre-passage density. 
2.4. Bioprinting of PLGA-PEG Microparticle Pastes 
The Fab@Home platform (Model 2) [35] was used in conjunction with 16G tapered dispense tips (Adhesive 
Dispensing, Milton Keynes, UK) for microparticulate construct fabrication. To prevent early sintering of 
microparticles all materials were pre-cooled to 4oC and wherever possible sample preparation was carried 
out at this temperature as well. PLGA-PEG microparticles with or without a proportion of PLGA-based 
microspheres were mixed with aqueous carrier solutions containing one of the following viscosity modifiers 
- medium viscosity carboxymethyl cellulose (CMC) (catalogue number 12M8P, Ashland Speciality 
Ingredients, Poole, UK), high viscosity CMC (catalogue number 12M31P, Ashland) or Pluronic® F-127 (Sigma-
Aldrich). The concentrations of these modifiers were in the range 0.1 – 4% (w/v) and the solutions were 
mixed with the solid components at various v:w ratios in the range 1:1 – 1.7:1. The resulting pastes were 
loaded into syringe barrels for deposition using a material flow rate of 38.8 μL s-1. 
For the accuracy of unconfined compression testing it was important that bioprinted constructs had 
identical shapes and sizes and that they could be tested without the need for them to be trimmed. In order 
to achieve this PLGA-based microparticulate pastes were extruded into poly(tetrafluoroethylene) (PTFE) 
cylindrical moulds 6 mm in diameter and 12 mm in height. The current printing resolution is insufficient for 
producing such compression testing samples with precise shape and uniformity. 
In order to incorporate cells into bioprinted pastes, suspensions of ihMSCs in PBS were first manually mixed 
by stirring with acellular solutions of high viscosity CMC to a final CMC concentration of 2% (w/v) and a final 
cell density of 2 x 106 mL-1. The resulting cell suspensions were then combined with microparticles in a 1.4:1 
(v:w) ratio for bioprinting. 
2.5. Unconfined Compression Testing 
Three sintered constructs per condition were subjected to unconfined compression testing using a 
TA.HDplus texture analyser (Stable Micro Systems, Godalming, UK). Samples were tested at 37oC 
immediately at the end of 24 hours sintering. The probe movement rate was 0.04 mm s-1 (which equates to 
a 0.333% s-1 strain rate) and the test was continued to 50% strain. 
2.6. Scanning Electron Microscopy and Micro-Computed Tomography 
SEM was performed using a JSM 6060LV (JEOL, Welwyn Garden City, UK). Images were taken at a minimum 
of three different magnifications and in three different quadrants of each sample and three samples were 
imaged per condition. Micro-computed tomography (μCT) imaging was undertaken using a Skyscan 1174 
(Bruker microCT, Kontich, Belgium). This analysis was performed on three samples per condition. Images 
were taken at 6.7 μm resolution every 0.4o of rotation from 0 to 180o and at each rotation step a total of 6 
frames were averaged to produce the final image. The NRecon software provided by the manufacturer was 
used to reconstruct cross-sectional slices with ring artefact reduction set to 20, beam hardening to 20% and 
consistent thresholding across all samples. Finally CTAn was used to produce three-dimensional models of 
scanned samples and to perform analyses such as measurements of total porosity and pore size 
distribution. As with reconstruction in NRecon, consistent thresholding was applied across all samples to be 
compared and despeckling was also performed to remove objects of 100 voxels or less from reconstructed 
images prior to analysis and modelling. 
2.7. Measurement of Protein Release Rate from Microspheres 
To produce constructs for assessment of post-bioprinting lysozyme release rate and activity 
microparticle/microsphere mixtures were formulated into pastes using 2% (w/v) high viscosity CMC at a 
1.4:1 (v:w) ratio. Pastes containing 400 mg of solid were then extruded into PTFE moulds and sintered for 
two hours prior to submersion in 3 mL of pre-warmed (37oC) PBS in 15 mL centrifuge tubes to initiate 
protein release. This study was conducted in triplicate and compared constructs containing lysozyme-
loaded microspheres with those containing blank microspheres. Incubation was continued at 37oC for a 
period of 15 days under gentle agitation and at regular intervals the PBS was completely aspirated, assayed 
for total protein content and lysozyme activity and replaced. 
The Micro BCA Protein Assay Kit (Fisher Scientific) was used to quantify the total protein content of 
aspirated release medium.  As per manufacturer’s instructions 150 μL of each sample or standard was 
mixed in a 96-well plate well in triplicate with 150 μL of complete working reagent. After 2 hours incubation 
at 37oC, the absorbance of the mixture in each well was measured at 562 nm. 
The ability of lysozyme to lyse Micrococcus lysodeikticus bacteria was used to measure protein activity in 
release medium, which was compared to the total lysozyme released as calculated from BCA assay results.  
In triplicate in the wells of a 96-well plate 150 µL of each standard or sample was mixed with 100 µL of 2.3 
mg mL-1 M. lysodeikticus suspension (Sigma-Aldrich).  The drop in absorbance due to cell lysis over a three 
minute period was then read at 450 nm at 37oC. 
2.8. Viability Assessment of Cells in PLGA-PEG Pastes 
Pre-bioprinting ihMSC counting and viability assessment were performed using an improved Neubauer 
haemocytometer and trypan blue (Fisher Scientific, Loughborough, UK) dye exclusion. The extruded 
material was incubated at 37˚C in humidified environment for 30mins to allow the particles to fuse before 
immersion in culture medium. For each time point, three samples were made. For imaging cells, the 
extruded constructs were disassembled manually to expose the cells and then submerged in a 2μM/4μM 
calcein AM/ethidium homodimer-1 (live/dead) solution (Life Technologies) and incubated for 45 minutes. 
Samples were imaged using a Leica DM IRB inverted microscope (Leica Microsystems (UK), Milton Keynes, 
UK). Six fields of view were imaged for each of three samples to assess cell viability. 
2.9. Statistical Analysis 
The homogeneity of variances across experimental groups was determined by Levene’s test. Appropriate 
post hoc procedures were used after one way ANOVA for pairwise comparison of experimental groups. In 
cases of equal variance Tukey’s procedure was applied, whilst the Games-Howell procedure was used for 
cases of unequal variance. All statistical tests were performed at the 5% significance level. For comparing 
cell viability, two-way ANOVA and Tukey’s test were used with a α level of 0.05. 
3. Results & Discussion 
3.1. Feasibility of Bioprinting PLGA-Based Microparticulate Pastes 
The PLGA-based microparticulates used in this work must be suspended in the carrier liquid at high 
densities to generate large numbers of bridging contacts and consequently sufficient mechanical strength. 
Meanwhile, the mixture of microparticulates and liquid carrier needs to be extruded with consistent 
composition using the Fab@home model 2 bioprinting platform. We demonstrated that it was feasible to 
deposit the mixture using bioprinting by selecting the appropriate microparticle size, solid to carrier ratio 
and carrier concentration. Extruded microparticulate material could be sintered in PBS by a 
thermoresponsive sintering mechanism in which the glass transition temperature rose due to the leaching 
of the PEG compoonent. The size and shape of the bioprinted constructs were maintained after sintering, 
and sufficient mechanical integrity was acquired to allow handling and manipulation (figure 1). 
 
Figure 1 – Representative images of constructs produced via bioprinting of PLGA-PEG microparticles 
suspended in 3% medium viscosity CMC at a 1.4:1 (v:w) ratio of aqueous carrier to solid. Images are shown 
of constructs both before (left) and after (right) 24 hours sintering. Scale bars represent 2 mm. 
In order to allow consistent and controlled extrusion, the microparticulate pastes used in this study differed 
in several ways from those used in previous studies [22-27]. To prevent syringe tips from becoming clogged 
smaller microparticles were used than in previous studies, with the 50 – 100 μm size fraction isolated in 
place of the 100 – 200 μm fraction. In addition, to prevent syneresis (preferential ejection of the fluid 
component), a greater proportion of carrier fluid was used (carrier to solid ratio of 1.4:1 as opposed to 
0.6:1 – 1:1) and the concentration of medium viscosity CMC in the fluid was also increased (3% (w/v) as 
opposed to 0.5% (w/v)). Avoiding clogging and achieving ‘complete extrusion’ of the entire paste volume 
was considered a pre-requisite for ensuring that paste composition and thus ultimate mechanical 
properties remained consistent throughout fabrication. 
3.2. Optimising the Mechanical Properties of Bioprinted Constructs 
The next stage in the development of this bioprinting-based approach to fabricate constructs was to 
optimize the process with respect to mechanical properties. To achieve this aim, alternative viscosity 
modifiers were considered alongside the medium viscosity CMC used up to this point.  The minimum carrier 
to solid (v:w) ratios that permitted complete extrusion of microparticle pastes without syringe tip clogging 
are shown in Table 1. Pluronic® F127 was investigated alongside CMC as having potential to directly 
lubricate microparticle-microparticle interactions. It was found that as well as requiring larger ratios than 
the best concentrations of CMC to achieve complete extrusion (table 1), all concentrations of Pluronic® 
F127 produced pastes which displayed liquid-like behaviour after deposition and did not allow structures or 
patterns to be maintained through the sintering process. 
It can be reasonably expected that a larger proportion of carrier leads to less microparticle-to-microparticle 
contacts and thus lower mechanical strength. The conditions which allowed the least liquid carrier to be 
used to achieve consistent extrusion without the syringe tips becoming clogged were considered optimal 
and were carried forward for further evaluation. On the basis of the results shown in table 1 the three most 
promising carriers were 3% (w/v) medium viscosity CMC, 2% (w/v) high viscosity CMC and 3% (w/v) high 
viscosity CMC. 
Table 1 – Minimum v:w ratios of a variety of aqueous carriers to solid required to produce PLGA-PEG 
microparticle pastes which could be extruded in their entirety by Fab@Home Model 2 bioprinting platform. 
Failure to achieve ‘complete extrusion’ indicates syneresis, tip clogging and inconsistent paste composition.
Carrier Minimum Carrier to Solid Ratio (v:w) 
0.5% (w/v) Medium Viscosity CMC 1.7:1 
1% (w/v) Medium Viscosity CMC 1.7:1 
2% (w/v) Medium Viscosity CMC 1.6:1 
3% (w/v) Medium Viscosity CMC 1.4:1 
0.5% (w/v) High Viscosity CMC 1.7:1 
1% (w/v) High Viscosity CMC 1.5:1 
2% (w/v) High Viscosity CMC 1.4:1 
3% (w/v) High Viscosity CMC 1.3:1 
0.5% (w/v) Pluronic® F127 1.6:1 
1% (w/v) Pluronic® F127 1.5:1 
2% (w/v) Pluronic® F127 1.5:1 
3% (w/v) Pluronic® F127 1.5:1 
 
The mechanical properties of constructs produced using the chosen combinations were then 
assessed using unconfined compression testing, both at the derived minimum ratios of carrier to 
solid and at ratios either side. Close rations at either side of the minimum ratios were selected 
because tip clogging was sensitive to small changes in the carrier/solid ratio. The additional ratios 
were intended to indicate in principle whether any additional mechanical strength could be obtained 
by intentionally making the pastes ‘too wet’ or ‘too dry’. On the basis of the yield stresses (figure 2) 
and Young’s moduli (figure 3) of bioprinted constructs, 2 and 3% (w/v) high viscosity CMC (both at 
minimum ratios) appeared to be the most promising carriers for construct fabrication. These 
constructs had yield stresses of 1.22 and 1.15 MPa and Young’s moduli of 54.4 and 57.3 MPa 
respectively. These values are lower than those obtained in other bone tissue engineering studies 
with harsher fabrication processes [1-4, 8, 10-12] but are nonetheless within the normal ranges for 
cancellous bone [28-31, 36, 37].  
 
Figure 2 – Yield stresses for bioprinted PLGA-PEG microparticulate scaffolds as assessed by 
unconfined compression testing (n = 3). PLGA-PEG microparticles were suspended in a variety of 
aqueous carriers at a variety of carrier to solid (v:w) ratios for bioprinting into cylindrical PTFE 
moulds. Samples were tested after 24 hours sintering. Error bars show one standard deviation and 
statistically-significant differences are denoted by (*). 
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 Figure 3 – Young’s moduli for bioprinted PLGA-PEG microparticulate scaffolds as assessed by 
unconfined compression testing (n = 3). PLGA-PEG microparticles were suspended in a variety of 
aqueous carriers at a variety of carrier to solid (v:w) ratios for bioprinting into cylindrical PTFE 
moulds. Samples were tested after 24 hours sintering. Error bars show one standard deviation and 
statistically-significant differences are denoted by (*). 
In general, constructs dispensed with high viscosity carriers showed higher mechanical properties 
than those produced with the medium viscosity carrier. In a construct produced using medium 
viscosity CMC there is likely to be a more heterogeneous distribution of microparticles, creating 
‘strong points’ and ‘weak points’ within the structure. The mechanical behaviour of the constructs 
will then result from the properties of the weak points more than the strong and the constructs as a 
whole will be less strong and yield more readily. This effect will be lessened in constructs produced 
using the high viscosity carriers as these are more effective at preventing syneresis and ensuring 
homogeneous distributions of microparticles. 
Compression testing showed no significant differences between constructs produced using the same 
carrier with different carrier to solid ratios and so subsequent analysis was performed only on the 
central ratios. µCT and SEM imaging were used to measure and visualise the pore structures of 
constructs produced using the different carrier solutions. Constructs produced using 2 and 3% (w/v) 
high viscosity CMC had relatively low porosities of 10.8 and 12.4% respectively (figure 4) and these 
values are reflected in the relatively dense structures seen via SEM imaging (figure 5). Constructs 
produced using medium viscosity CMC as a carrier showed porosities which were not statistically 
different to those of other constructs. However the variability seen with this carrier was much higher 
than with others. This again suggested the inability of medium viscosity CMC to prevent syneresis, 
which resulted in large variations in porosity between different constructs. 
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 Figure 4 – Porosities of bioprinted PLGA-PEG microparticulate scaffolds as assessed by μCT imaging 
and analysis (n = 3). PLGA-PEG microparticles were suspended in a variety of aqueous carriers at 
different carrier to solid (v:w) ratios for bioprinting into cylindrical PTFE moulds. Samples were tested 
after 24 hours sintering. Error bars show one standard deviation. 
   
   
Figure 5 – SEM  (upper row) and representative µCT (lower row) images of cross-sectional fracture 
surfaces of bioprinted PLGA-PEG microparticulate scaffolds. PLGA-PEG microparticles were 
suspended in a variety of aqueous carriers for bioprinting into cylindrical PTFE moulds. Constructs 
were fractured after 24 hours sintering. Left to right - 3% (w/v) medium viscosity CMC used at 1.4:1 
(v:w) carrier to solid ratio, 2% (w/v) high viscosity CMC at 1.4:1 ratio and 3% (w/v) high viscosity CMC 
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at 1.3:1 ratio. All µCT images used for porosity and pore size measurement are shown in 
supplementary figure 1. 
The mean pore sizes for constructs produced using 2 and 3% (w/v) high viscosity CMC carriers were 
65.3 and 76.6 μm (figure 6). It was found that constructs produced using 2% (w/v) high viscosity CMC 
had statistically smaller mean pore sizes than those produced with other carriers. This may suggest 
that this carrier is the most effective at ensuring homogenous microparticle distribution. It has been 
suggested that an optimal construct for bone regeneration needs to contain a large population of 
pores of around 200 – 400 μm in size in order to maximize tissue ingrowth [38-41]. The pores 
produced here were mostly smaller than this suggested range but many were large enough to allow 
cell motion and proliferation in the constructs, based on the results of previous studies in bone 
tissue engineering [42, 43]. Additionally with appropriate development and optimisation it may be 
possible to create pores in this desired size range by designing them into the bioprinted construct 
architecture. 
 
Figure 6 – Mean pore sizes of bioprinted PLGA-PEG microparticulate scaffolds as assessed by μCT 
imaging and analysis (n = 3). PLGA-PEG microparticles were suspended in a variety of aqueous 
carriers at different carrier to solid (v:w) ratios for bioprinting into cylindrical PTFE moulds. Samples 
were tested after 24 hours sintering. Error bars show one standard deviation and Statistically-
significant (p < 0.05) differences are denoted by (*). 
3.3. Incorporation of Cells and Proteins in Bioprinted Constructs 
Besides achieving mechanical properties that match with bone, incorporating biological factors such 
as cells and growth factors in the scaffold can potentially accelerate healing of complex bone 
defects. The ability to print the PLGA-PEG material at ambient temperature enables the 
incorporation of temperature-sensitive components such as cells and proteins in a spatially defined 
manner. The differentiation of MSCs in moulded scaffolds made of PLGA-PEG and PLGA particles has 
been studied previously [44]. As an initial study, here we investigated the bioactivity and viability of 
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homogeneously incorporated proteins and cells. We first investigated the incorporation of 
therapeutic proteins. Using an approach utilized extensively by our group [33, 45] and others [5, 46-
49] lysozyme was incorporated into PLGA-based microspheres by a water-in-oil-in-water double 
emulsion technique. A PLGA-PEG-PLGA triblock copolymer [33] was used to modify the protein 
release profile. Lysozyme was being used here as a model protein for bone morphogenetic protein-
2, which is a potent growth factor involved in bone development and repair [50-53]. Lysozyme was 
chosen on the basis of the two proteins’ similar molecular weights and isoelectric points. These 
protein-loaded microspheres were then incorporated into microparticle pastes used for bioprinting, 
with previous work suggesting a 3:1 (w:w) ratio of microparticles to microspheres as a suitable 
starting point [44]. 
A release study was undertaken to assess the controlled release of active protein from microspheres 
which had been incorporated into microparticulate pastes for bioprinting. In this study constructs 
containing lysozyme-loaded microspheres were found to be capable of delivering active protein for a 
period of at least 9 days (figure 7). The protein released by the microspheres was predominantly 
active (≥ 61%), with no clear drop in activity observed across this period. Beyond the ninth day after 
the start of the study the total activity of released protein dropped below the sensitivity of the 
Micrococcus assay, but protein release could be observed by micro BCA assay up to the fifteenth day 
(Supplementary Figure 2). This suggests that optimisation of the microsphere formulation would 
allow active protein to be delivered over significantly longer periods as in previous studies [45]. 
 
Figure 7 – Lysozyme release from PLGA microspheres encapsulated within bioprinted PLGA-PEG 
microparticulate constructs. A 9:1 (w:w) mixture of HSA and lysozyme was encapsulated in PLGA 
microspheres via a double emulsion protocol with a total protein content of 1% (w/w) relative to 
polymer. Expected activity levels are one tenth of total protein level measured by Micro BCA assay. 
Error bars represent one standard deviation. 
The incorporation of non-sintering microspheres as described above can potentially lower the 
mechanical properties of PLGA-PEG microparticulate constructs by reducing the number of bridging 
contacts between the thermoresponsive microparticles. This effect needs to be addressed in future 
studies aimed at further optimising the construct production process. However, the reduction in 
mechanical strength may be lessened by reducing the proportion of microspheres in the constructs. 
Previous studies showed that the amount of protein encapsulated in a given mass of microspheres 
could be varied over approximately an order of magnitude whilst maintaining good encapsulation 
efficiency [33, 45, 54]. Increasing the ratio of protein to polymer would allow fewer microspheres to 
be incorporated whilst maintaining the total protein load per construct, and this would allow better 
retention of mechanical properties. 
A further key step in the process development undertaken here was the incorporation of live cells in 
the production process. Cells were mixed manually using a plastic spatula into the microparticulate 
pastes and the effects of factors such as the cell density were not investigated at this stage. The 
viability of cells was found to be dependent on the carrier to solid ratio. The cell viabilities for the 
1.5:1 ratio were 87% and 77% at day 0 and day 1, respectively. Decreased cell viabilities were found 
for a higher ratio (1.4:1) at both time points. The viability for the 1.4:1 ratio dropped below 50% at 
day 1. This demonstrated that a small change in carrier:particle ratio could have a significant effect 
on cell viability. The yield stress and Young’s modulus for the 1.5:1 ratio material was lower than 
those of 1.4:1 but not statistically significant. We think that the significant drop in cell viability could 
be due to reduced lubrication resulted from a smaller amount of viscous carrier. A small reduction in 
lubrication could significantly increase the mechanical stress on cells during extrusion though a 
needle.  
  
Figure 8 – Fluorescence microscopy images of live/dead (calcein AM/ethidium homodimer-1) stained 
ihMSCs bioprinted at 2 million cells per mL in a microparticulate paste composed of PLGA-PEG 
microparticles suspended in 2% high viscosity CMC at two carrier to solid ratios (v:w).Data are 
presented as means±SD (n=18). * Data statistically analysed by two-way ANOVA and Tukey’s test 
assuming confidence levels of 95% (p<0.05).Scale bar=100 µm 
4. Conclusions 
The work presented here has demonstrated the essential feasibility of using bioprinting and a 
thermo-responsive material to produce constructs which have mechanical properties comparable to 
cancellous bone. The mild conditions used for bioprinting and material sintering have allowed viable 
cells and active therapeutic proteins to be incorporated into the construct production process. The 
approach adopted in this study has the potential for patterning biological constituents within 
constructs to achieve more sophisticated architectures, which circumvents the problems associated 
with post-fabrication cell seeding and biomolecule addition. The complexity of the final printed 
scaffold will depend on individual applications in which the scaffold is intended to be used. 
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Supplementary 
   
   
   
Figure 1. Micro-CT images were used to calculate porosity and pore size. From upper row to bottom 
row - 3% (w/v) medium viscosity CMC used at 1.4:1 (v:w) carrier to solid ratio, 2% (w/v) high viscosity 
CMC at 1.4:1 ratio and 3% (w/v) high viscosity CMC at 1.3:1 ratio. 
 
 
Figure 2. Lysozyme release from PLGA microspheres encapsulated within bioprinted PLGA-PEG 
microparticulate constructs (PLGA-PEG:PLGA=3:1 w/w). A 9:1 (w:w) mixture of HSA and lysozyme 
was encapsulated in PLGA microspheres via a double emulsion protocol with a total protein content 
of 1% (w/w) relative to polymer.  
 
 
